Skip to content
Bored Studies
RecruitingPhase 2

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

ADARx Pharmaceuticals, Inc. · NCT06990269

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 60+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
240
US sites recruiting
19
Study start
November 10, 2025
Record last updated
September 3, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.

Being studied: ADX-038; Placebo

Conditions: Geographic Atrophy Secondary to Age-related Macular Degeneration

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Clinical diagnosis of GA of the macula secondary to AMD
  • GA lesions between 2.5 and 12.5 mm2 at screening
  • Sufficiently clear ocular media, adequate pupillary dilation and fixation to permit quality fundus imaging in the study eye as described in the protocol
  • Willing and able to comply with clinic visits and study-related procedures, including completion of the full series of meningococcal vaccinations and pneumococcal vaccination required per protocol

Exclusion Criteria

  • Has GA secondary to causes other than AMD
  • Has active ocular disease that compromises or confounds visual function
  • History of surgery for retinal detachment
  • Has ocular condition other than GA secondary to AMD
  • Use of intravitreal complement inhibitors in study eye
  • Hereditary or acquired complement deficiency
  • Active viral, bacterial or fungal infection
  • Liver injury as evidenced by abnormal liver function tests
  • Donating blood
  • History of choroidal neovascularization in the study eye

Recruiting US locations

Study contacts (from the official record)

  • Nali Castillo · 877-232-7974 · info@adarx.com
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy (NCT06990269) | Bored Studies